Skip to main content
Premium Trial:

Request an Annual Quote

AnPac Bio Prices Public Offering of American Depositary Shares

NEW YORK – AnPac Bio-Medical Science said late on Tuesday that it has priced an underwritten public offering of 1,301,928 American Depositary Shares at $2.22 per share.

Gross proceeds from the offering are estimated at approximately $2.9 million, including the full exercise of the underwriter's over-allotment option. EF Hutton is the sole bookrunning manager for the offering.

AnPac's shares on the Nasdaq were down about 23 percent at $1.89 in morning trading on Wednesday.

The company, which has its headquarters in Shanghai and Ambler, Pennsylvania, is developing a diagnostic device to differentiate 11 cancer types based on biophysical properties of blood components. In August, AnPac and Roche Pharmaceuticals China announced they would work together to combine their cancer screening, diagnostic, and treatment-guiding technologies into personalized product lines.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.